BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization
China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...
SHE: 000999
CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...
CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned...
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...
CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million
China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase...
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...
Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China
Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned...
Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare
The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership...